Penumbra, Inc. (PEN) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsHold20 analystsPrice History
5-Year Weekly Candlestick Chart
Profile
Strong financial health, earnings quality and growth.
How is each axis scored?
- Valuation52/100 · Moderate
- P/E vs own history (16th pct)25/25
- FCF yield (1.7%)5/25
- P/S (8.7x)12/25
- EV/EBIT (n/a)10/25
- Growth82/100 · Strong
- Revenue CAGR (17.1%)20/25
- Net income CAGR (140.8%)25/25
- EPS CAGR 5Y (138.6%)25/25
- Fwd implied growth (8.8%)12/25
- Profitability64/100 · Moderate
- ROIC (17.2%)20/25
- ROE (11.6%)12/25
- Net margin (11.8%)20/25
- Operating margin (12.9%)12/25
- Financial Health100/100 · Strong
- Altman Z (19.00)25/25
- Current ratio (6.02)25/25
- Interest coverage (no interest expense)25/25
- Net cash / debt (Net cash)25/25
- Quality87/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.49)20/25
- FCF conversion (124%)25/25
- Margin stability (σ 6.1%)20/25
About Penumbra, Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. Show more
The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Headquarters: ALAMEDA, CA · Employees: 4,700 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellTax withholding · filed 2026-09-17-1230 sh2026-09-15
- BuyGrant / award · filed 2026-08-19+3.1K sh2026-08-17
- SellGift · filed 2026-05-21-77000 sh2026-05-19
- SellOpen market sale · filed 2026-04-06-100 sh2026-04-02
- SellTax withholding · filed 2026-03-17-117 sh2026-03-15
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
52CP/E (TTM)73.9xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 54.0x–2052.2x · 16th pct
P/FCF58.3xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.7%C
Grade C: LowTTM FCF / Market Cap — vs own 5Y history: -1.6%–1.8% · 95th pct
P/S (TTM)8.66xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 5.6x–15.3x · 41st pct
EV/EBITDA66.0xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales8.2xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E67.9xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio8.54xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio9.84D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
64BROIC17.2%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE11.6%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA8.6%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin11.8%A
Grade A: HighNet Income / Revenue
Operating Margin12.9%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin67.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin14.6%C
Grade C: AverageFCF / Revenue
True FCF Margin10.5%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
100A+Altman Z-Score19.00A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio6.02xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio4.01xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage—
EBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.02xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Growth
82ARevenue CAGR17.1%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR140.8%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)138.6%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth8.8%B
Grade B: LowImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)+5.4%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income35.1%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.1%C
Grade C: MedTTM stock-based comp / TTM Revenue
Quality
2/10 Loss Years87APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.49A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion124.4%A
Grade A: StrongFCF / Net Income
Margin Stability6.1%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue4.4%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.77xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)$4.33
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$13.89
Cash & short-term investments per share (Finnhub)
Book Value / Share$36.39
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$615.66M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$1.47B
Shareholders' equity (book value)
Asset / Liability4.47xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$12.59B
Current Market Capitalization
Beta0.71B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash. · Current P/E of 73.9x sits at the 16th percentile of its historical range.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 25, 2026
Key Insights: Penumbra, Inc. (PEN)
Penumbra, Inc. meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 19.00 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.49 suggests a low likelihood of earnings manipulation.
- Revenue has compounded at roughly 17% annually, with net income growing about 141% per year — a strong growth profile.
- Company is effectively debt-free after netting cash.
- Penumbra, Inc. posted a net loss in 2 of 10 available completed fiscal years (2016–2025).
See how PEN ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for PEN in the last 30 days.
See PEN move history →Frequently Asked Questions about PEN
Is PEN stock a buy right now?
PreMarketPrice's quantitative model rates Penumbra, Inc.'s financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is PEN stock overvalued?
Penumbra, Inc. trades at a trailing P/E of 73.9 and our valuation score rates it 52/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Penumbra, Inc. report earnings?
No confirmed earnings date is currently scheduled for PEN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Penumbra, Inc. operate in?
Penumbra, Inc. operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Penumbra, Inc. do?
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots.
About Penumbra, Inc. (PEN) Stock
Penumbra, Inc. (PEN) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. Real-time pricing data for Penumbra, Inc. is available on this page with a market capitalization of $12.6 billion. The financial health score for PEN is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for PEN stock.
PEN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Penumbra, Inc. (PEN) across multiple dimensions:
- Pre-market price & movement: Real-time PEN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for PEN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Penumbra, Inc. across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for PEN.
- Sector peers: Compare PEN against 10 other healthcare stocks on key financial metrics.
Is PEN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Penumbra, Inc. (PEN) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Penumbra, Inc. (PEN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.